La transacción es de gran importancia para el grupo liderado por Walter Bertin, ya que permite a Labomar fortalecer su posición en el sector de los cosméticos funcionales y acceder más de cerca a ...
Develco Pharma is a specialty pharmaceutical company that develops and produces innovative formulations for drugs with known active ingredients. After approval, the products are licensed out to intern...
This round was led by Faraday Venture Partners, among others. Additionally, the round received backing from previous investors like Demium and the Bacoy Management family office, who have reaffirmed t...
The dental laboratory sector represents an attractive investment opportunity within Spain’s €8bn oral healthcare market. With c. 3,800 laboratories across the country, the sector is highly fragmen...
Adventia Pharma y ProA Capital han alcanzado un acuerdo según el cual, ambas empresas afrontarán conjuntamente el crecimiento de Adventia Pharma y de Nutrición Médica (esta última recientemente a...
Asabys Partners announced today the successful final close of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII II) with total commitments of €180 million ($200M), exceeding i...
Be levels, a leading company in the health sector specializing in nutritional and sports supplements based on natural active ingredients, has announced that Axon Partners Group has acquired a minority...
Autoscriber offers an ambient clinical intelligence product that supports doctors during the patient consultation using speech-based AI technology. The software automatically generates structured clin...
The fund's investment strategy, which aims to reach €50 million, focuses on innovative companies that are in the commercial phase or close to the commercialization of their products and services, in...
La gestora de capital riesgo Clave Capital ha participado en la primera ronda de inversión institucional de Homedoctor, empresa líder en medicina digital. Esta exitosa operación también ha contado...
Bio & Tech Smart Capital FCRE, fondo de capital riesgo de Noso Capital, lidera la ronda de inversión abierta por ADNTRO Genetics que asciende a 1 millón de euros, para impulsar la expansión de N-GE...
After announcing an initial closing of 100 million in February of this year, the hard cap set for the Fund has been reached. The investment strategy consists on supporting high-growth companies in sec...